Amerisource Health Services Recalls Paricalcitol Capsules Due to Impurities
Amerisource Health Services is recalling 648 cartons of Paricalcitol Capsules, 1 mcg, due to failed impurities specifications.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which by definition is unlikely to cause adverse health consequences, aligning with the Low severity criteria for minor or theoretical risks.
Plain-English summary
Amerisource Health Services is recalling 648 cartons of Paricalcitol Capsules, 1 mcg, packaged in 30 capsules per carton. The product is distributed by American Health Packaging in Columbus, Ohio, and is available by prescription only. The recall covers Lot 154341 with an expiration date of 03/17.
The recall was initiated because the repackaged product failed results for impurities. The FDA has classified this recall as Class III, which indicates that use of or exposure to the product is not likely to cause adverse health consequences.
Healthcare providers and patients should stop using the affected product and contact their pharmacist or healthcare provider for further instructions. The recall is distributed nationwide.
The recalled product
- Product
- Paricalcitol Capsules, 1 mcg, packaged in 30 Capsules (5 x 6) per carton (NDC 60687-106-25); each blister card containing 6 individually blistered capsules (NDC 60687-106-95), Rx only, Distributed by: American Health Packaging, Columbus, OH, 43217.
- Manufacturer
- Amerisource Health Services
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 648
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 154341
- Exp 03/17
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Amerisource Health Services
See all →- HighAmerisource Recalls Paroxetine Tablets Due to Foreign Object Presence
FDA (Drugs) · 2017-11-29
- LowAmerisource Recalls Enalapril Maleate Tablets Due to Stability Failures
FDA (Drugs) · 2017-11-22
- ModerateAmerisource Recalls Glipizide Extended-Release Tablets Due to Dissolution Failure
FDA (Drugs) · 2017-03-22
- ModerateCyclosporine Capsules Recalled for Impurity Specification Failures
FDA (Drugs) · 2017-03-08
- ModerateAHP Nifedipine Capsules Recalled for Presence of Foreign Tablets
FDA (Drugs) · 2016-11-30
Same hazard · impurities
See all →- ModerateCipla Recalls Fosfomycin Tromethamine Due to Impurity Specification Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Specifications
FDA (Drugs) · 2026-10-14
- LowMacleods Recalls Olanzapine Tablets Due to Impurity Levels
FDA (Drugs) · 2026-09-30
Similar recalls
- HighAmerisource Recalls Hydrochlorothiazide Capsules Due to Particulate Matter
FDA (Drugs) · 2016-01-20
- LowAmerisource Recalls Candesartan Cilexetil Tablets Due to Impurity Failures
FDA (Drugs) · 2016-02-17
- LowAmerisource Recalls Fenofibrate Capsules Due to Incorrect or Missing Labeling
FDA (Drugs) · 2016-04-20
- HighAmerisource Recalls Paroxetine Tablets Due to Foreign Object Presence
FDA (Drugs) · 2017-11-29
- ModerateHydrALAZINE Hydrochloride Tablets recalled due to impurity specifications failure
FDA (Drugs) · 2023-10-11
- LowAmerisource Health Services Recalls Fenofibrate Capsules Due to Labeling Errors
FDA (Drugs) · 2016-04-20